W
bioLLM/wiki

AI-Curated Biotech/Medical Knowledge Base
Live
Back to List View Graph View

Combination therapy

Combination therapy is the use of two or more therapeutic agents, treatment modalities, or biologically distinct interventions to address a disease simultaneously.

Where the papers sit

21 papers from the last 6 months study combination therapy directly · updated from PubMed 1 Nov 2026

Study type 1 clinical trial · 2 observational · 6 human data · 9 preclinical · 3 unclassified

Themes one subject · 1 new direction

Those 21 are all about one subject.

  • Broad Translational Therapeutics

    Therapeutic development spans inflammatory disease, cancer, infection, neurodegeneration and antibiotic resistance. Drug pairs, biologic combinations and computationally predicted synergies are assessed alongside safety, biomarkers and real-world effectiveness. Reported goals include reversing treatment resistance, improving immune responses and rescuing tissue injury. No shared mechanism, disease focus or consistent clinical direction unites the set.

    21 papers

NEW DIRECTION

Combination therapy is used to map tumor–immune state transitions rather than only to improve treatment efficacy

The tumor–immune model incorporating immune checkpoint inhibitors and CCR2 antagonists treats combination therapy as a dynamical perturbation whose role is to reveal transcritical, saddle-node, and cusp bifurcations, multiple tumor equilibria, and quantitative regime boundaries calibrated against murine data, rather than as a regimen evaluated primarily for response, resistance reversal, or survival benefit. This changes combination therapy from an intervention to be selected or validated into a tool for characterizing how therapeutic parameters reorganize the underlying tumor–immune system and for identifying conditions under which qualitatively different disease states emerge. 42562918Aug

Papers

The 21 papers from the last 6 months that study combination therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Broad Translational Therapeutics (21)
  1. Real-World Effectiveness and Safety of Advanced Combination Treatment in Patients with Refractory Inflammatory Bowel Disease. Advances in therapy · 15 Oct 2026 PMID 42879110
  2. Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno-Oncology Combination Therapy. Clinical pharmacology and therapeutics · 7 Oct 2026 PMID 42844564
  3. Multi-omics-driven personalized management of advanced HCC. Cell reports. Medicine · 2 Oct 2026 PMID 42826719
  4. Class-imbalance-sensitive evaluation of automated decisions in mixed heart-lung auscultation. Physiological measurement · 18 Sept 2026 PMID 42759547
  5. From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells. PloS one · 16 Sept 2026 PMID 42748134
  6. Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data. Cell reports. Medicine · 11 Sept 2026 PMID 42727586
  7. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  8. Allosteric Inhibitors of Erythromycin Resistance Methyltransferase Reverse Antibiotic Resistance. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720463
  9. Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
  10. Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
  11. Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Seminars in arthritis and rheumatism · 3 Sept 2026 PMID 42691741
  12. CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism. Signal transduction and targeted therapy · 2 Sept 2026 PMID 42686681
  13. A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model. Molecular biomedicine · 2 Sept 2026 PMID 42684552
  14. Green analytical methods for quantification of a new combination therapy for amyotrophic lateral sclerosis: assessment by EPPI framework. Scientific reports · 21 Aug 2026 PMID 42624937
  15. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  16. Complex bifurcation dynamics of tumor-immune interactions incorporating combination therapies. Journal of mathematical biology · 7 Aug 2026 PMID 42562918
  17. A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347882
  18. Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer. Cancer research · 24 Jun 2026 PMID 42341181
  19. rSiglec-10(V set) armed oncolytic adenovirus improves the effects of virotherapy through enhancing oncolysis and antitumor immunity. International immunopharmacology · 18 Jun 2026 PMID 42314554
  20. Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 13 Jun 2026 PMID 42287952
  21. Azidothymidine potentiates the immunomodulatory function of interferon-α in adult T cell leukemia/lymphoma. Molecular therapy : the journal of the American Society of Gene Therapy · 12 Jun 2026 PMID 42281209

By study type

Clinical trials (1)
  1. A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347882
Observational studies and case reports (2)
  1. Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
  2. Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases. Seminars in arthritis and rheumatism · 3 Sept 2026 PMID 42691741
Human data, design not indexed (6)
  1. Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno-Oncology Combination Therapy. Clinical pharmacology and therapeutics · 7 Oct 2026 PMID 42844564
  2. Class-imbalance-sensitive evaluation of automated decisions in mixed heart-lung auscultation. Physiological measurement · 18 Sept 2026 PMID 42759547
  3. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  4. Allosteric Inhibitors of Erythromycin Resistance Methyltransferase Reverse Antibiotic Resistance. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720463
  5. Green analytical methods for quantification of a new combination therapy for amyotrophic lateral sclerosis: assessment by EPPI framework. Scientific reports · 21 Aug 2026 PMID 42624937
  6. Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer. Cancer research · 24 Jun 2026 PMID 42341181
Preclinical: animal, cell and lab studies (9)
  1. From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells. PloS one · 16 Sept 2026 PMID 42748134
  2. Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
  3. CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism. Signal transduction and targeted therapy · 2 Sept 2026 PMID 42686681
  4. A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model. Molecular biomedicine · 2 Sept 2026 PMID 42684552
  5. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  6. Complex bifurcation dynamics of tumor-immune interactions incorporating combination therapies. Journal of mathematical biology · 7 Aug 2026 PMID 42562918
  7. rSiglec-10(V set) armed oncolytic adenovirus improves the effects of virotherapy through enhancing oncolysis and antitumor immunity. International immunopharmacology · 18 Jun 2026 PMID 42314554
  8. Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 13 Jun 2026 PMID 42287952
  9. Azidothymidine potentiates the immunomodulatory function of interferon-α in adult T cell leukemia/lymphoma. Molecular therapy : the journal of the American Society of Gene Therapy · 12 Jun 2026 PMID 42281209
Unclassified: not yet indexed with MeSH (3)
  1. Real-World Effectiveness and Safety of Advanced Combination Treatment in Patients with Refractory Inflammatory Bowel Disease. Advances in therapy · 15 Oct 2026 PMID 42879110
  2. Multi-omics-driven personalized management of advanced HCC. Cell reports. Medicine · 2 Oct 2026 PMID 42826719
  3. Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data. Cell reports. Medicine · 11 Sept 2026 PMID 42727586
bioLLM/wiki is a literature-navigation aid for people who read primary research. It is not a medical resource, and it is not a substitute for a clinician, a pharmacist or the source papers themselves. Because the articles are drafted by language models, they can be incomplete or wrong in ways that read fluently. Please see the editorial policy and medical disclaimer before relying on anything here.

Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-09-10. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.